{
  "ticker": "LLY",
  "timestamp": "2025-12-01T08:36:00.266931",
  "analysis_date": "2025-06-16",
  "historical_mode": true,
  "summary": {
    "recommendations": {
      "technical": "SELL",
      "news": "BUY",
      "fundamental": "HOLD",
      "macro": "HOLD"
    },
    "valid_recommendations": {
      "technical": "SELL",
      "news": "BUY",
      "fundamental": "HOLD",
      "macro": "HOLD"
    },
    "confidence_levels": {
      "technical": "Medium",
      "news": "Low",
      "fundamental": "Medium",
      "macro": "Low"
    },
    "bull_signal_count": 34,
    "bear_signal_count": 17,
    "bull_rec_count": 1,
    "bear_rec_count": 1,
    "hold_rec_count": 2,
    "undetermined_count": 0,
    "analyst_count": 4,
    "valid_analyst_count": 4,
    "net_sentiment": "NEUTRAL"
  },
  "analyst_summaries": {
    "technical": "TECHNICAL: Uptrend confirmed, RSI 85 \u2192 SELL (Medium)",
    "news": "NEWS: Bullish sentiment (74 articles) \u2192 BUY (Low)",
    "fundamental": "FUNDAMENTAL: Overvalued \u2192 HOLD (Medium)",
    "macro": "MACRO: Mixed macro \u2192 HOLD (Low)"
  },
  "full_analyst_reports": {
    "technical": "[TECHNICAL] *** HISTORICAL MODE: Analyzing as of 2025-06-16 ***\n\n======================================================================\nTECHNICAL ANALYSIS: LLY\nAnalysis Period: 7 days\n*** HISTORICAL MODE: As of 2025-06-16 ***\nTimestamp: 2025-12-01 08:34:28\n======================================================================\n\n[TECHNICAL] Fetching 7-day price data for LLY...\n[TECHNICAL] \u2713 Historical: 51 days ending 2025-06-16\n[TECHNICAL]   Date range: 2025-04-03 to 2025-06-16\n[TECHNICAL] \u2713 Retrieved 51 days of data\n[TECHNICAL] Calculating technical indicators...\n[TECHNICAL] \u2713 Indicators calculated\n[TECHNICAL] Identifying support/resistance levels...\n[TECHNICAL] \u2713 Support: $706.41, Resistance: $821.98\n[TECHNICAL] Formatting technical summary...\n[TECHNICAL] Generating analysis with gpt-4o-mini...\n[TECHNICAL] \u2713 Analysis generated (1685 chars)\n\n[TECHNICAL] \u2713 Analysis complete in 11.08s\n======================================================================\n\n## Technical Analysis Summary\nAs of June 16, 2025, LLY is experiencing a strong uptrend with the current price at $804.63, showing a recent positive momentum yet facing overbought conditions in several indicators. The price is positioned within a high volatility environment, nearing a key resistance level.\n\n## Trend Assessment\n- **Primary Trend:** Uptrend\n- **Trend Strength:** Strong (as price is above most moving averages)\n- **Moving Average Alignment:** Bullish (price > EMA_10 > SMA_20 > SMA_50)\n\n## Momentum Indicators\n- **RSI:** 84.9 \u2192 **Overbought** (indicating potential for a pullback)\n- **MACD:** 11.955 | Signal: 2.357 | Histogram: 9.599 \u2192 Strong bullish momentum\n- **Stochastic:** %K=84.2, %D=90.4 \u2192 Overbought territory (confirming potential overextension)\n\n## Support & Resistance Levels\n- **Key Support:** $706.41\n- **Key Resistance:** $821.98\n- **Current Position:** Near resistance (+2.2% from current price)\n\n## Volatility & Risk\n- **ATR:** $17.33 (Normal volatility)\n- **Bollinger Bands:** Current price at $804.63 indicates it is positioned in the middle range of the bands ($685.82 - $827.49), with wide bands suggesting high volatility.\n\n## Trade Setup (If Applicable)\n**Entry:** $804.63  \n**Stop Loss:** $778.64 (Risk: $25.99)  \n**Target:** $821.98 (Reward: $17.36)  \n**Risk/Reward:** 0.67:1 (Poor risk/reward ratio)\n\nRECOMMENDATION: **SELL** - Confidence: Medium  \n- Given the overbought condition indicated by the RSI and Stochastic, along with a poor risk/reward ratio for a long setup, it would be advisable to consider exiting or shorting the position rather than entering long at this juncture. The proximity to resistance further supports this caution.\n",
    "news": "[NEWS] *** HISTORICAL MODE: Analyzing as of 2025-06-16 ***\n\n======================================================================\nNEWS & SENTIMENT ANALYSIS: LLY\n*** HISTORICAL MODE: As of 2025-06-16 ***\nPeriod: Last 7 days | Sources: ['yahoo', 'finnhub']\nTimestamp: 2025-12-01 08:34:42\n======================================================================\n\n[NEWS] \ud83d\udd27 Fetching Yahoo Finance news...\n[NEWS] \u26a0\ufe0f Yahoo Finance has limited historical news support\n[NEWS] \u2713 Yahoo Finance: 0 articles\n[NEWS] \ud83d\udd27 Fetching Finnhub news...\n[NEWS] Finnhub: Fetching news from 2025-06-09 to 2025-06-16\n[NEWS] \u2713 Finnhub: 74 articles\n[NEWS] \ud83d\udccb Enhancing 74 articles with background context\n[NEWS] \u26a0\ufe0f Date 2025-06-16 is past LLM knowledge cutoff (2024-01-01)\n[NEWS] \u26a0\ufe0f Skipping LLM context to prevent hallucination\n[NEWS] Analyzing with gpt-4o-mini...\n[NEWS] \u274c LLM error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-KtddXWX7pT8yz52FN9uLjN7j on requests per day (RPD): Limit 10000, Used 10000, Requested 1. Please try again in 8.64s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'requests', 'param': None, 'code': 'rate_limit_exceeded'}}\n[NEWS] Creating fallback analysis...\n\n[NEWS] \u2713 Analysis complete in 18.51s\n======================================================================\n\n# News & Sentiment Analysis: LLY\n**\u26a0\ufe0f HISTORICAL ANALYSIS AS OF 2025-06-16 \u26a0\ufe0f**\n**Analysis Period:** Last 7 Days\n**Date:** 2025-12-01 08:34\n\n======================================================================\n\n## Yahoo Finance News (7 Days before 2025-06-16)\n\nNo news found in the specified period\n(Historical mode: news before 2025-06-16)\n## Finnhub News (2025-06-09 to 2025-06-16)\n\n**Found 74 articles**\n\n1. **Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports**\n   - Source: Yahoo\n   - Published: today\n   - The drug maker's acquisition bid includes a payment of almost $1 billion upfront for Verve, and a further $300 million based on the genetic medicines ...\n\n2. **Why Novo Nordisk Stock Sank by Nearly 4% Today**\n   - Source: Yahoo\n   - Published: today\n   - On top of that, an analyst cut his price target on the Denmark-based pharmaceutical company.  Novo Nordisk (NYSE: NVO) stock had a Monday to forget, a...\n\n3. **Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts**\n   - Source: Yahoo\n   - Published: today\n   - In the closing of the recent trading day, Eli Lilly (LLY) stood at $807.58, denoting a -1.44% move from the preceding trading day....\n\n4. **Tracking Cliff Asness' AQR Capital Management 13F Portfolio - Q1 2025 Update**\n   - Source: SeekingAlpha\n   - Published: today\n   - AQR Capital's Q1'25 portfolio hits $97.07B, with top picks in AAPL, NVDA, & AMZN. Active portfolio adjustments show a quantitative, diversified approa...\n\n5. **Lilly to buy gene-editing partner Verve for up to $1.3 billion in cardiac care push**\n   - Source: Finnhub\n   - Published: today\n   - June 17 - Eli Lilly will acquire gene-editing startup VerveTherapeutics for up to $1.3 billion, the companies saidon Tuesday, to boost its pipeline of...\n\n6. **Eli Lilly strikes $1.3 billion deal to buy gene-editing biotech Verve Therapeutics, companies say**\n   - Source: Finnhub\n   - Published: today\n   - June 17 - Eli Lilly will acquire gene-editing startup VerveTherapeutics for up to $1.3 billion, the companies saidon Tuesday, sending Verve's shares u...\n\n7. **Eli Lilly Close To Buying Gene-Editing Biotech Verve Therapeutics - FT**\n   - Source: Finnhub\n   - Published: today\n   - June 16 - * ELI LILLY CLOSE TO BUYING GENE-EDITING BIOTECH VERVETHERAPEUTICS- FT * ELI LILLY IS IN ADVANCED TALKS TO BUY GENE EDITINGSTART-UPVERVE THE...\n\n8. **Novo Nordisk Stock Rises 6% in a Week: What Should Investors Do?**\n   - Source: Yahoo\n   - Published: today\n   - NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large....\n\n\n======================================================================\n\n## News & Sentiment Analysis\n*Generated using fallback analysis (LLM unavailable)*\n*Historical analysis as of 2025-06-16*\n\n**Data Sources:** 2 successful, 0 failed\n\n**Sentiment:** BULLISH\n- Bullish signals: 5\n- Bearish signals: 0\n\n**Total Articles:** 74\n\nRECOMMENDATION: BUY - Confidence: Low\n\n",
    "fundamental": "[FUNDAMENTALS] *** HISTORICAL MODE: Analyzing as of 2025-06-16 ***\n\n======================================================================\nFUNDAMENTAL ANALYSIS: LLY\n*** HISTORICAL MODE: As of 2025-06-16 ***\nTimestamp: 2025-12-01 08:35:02\n======================================================================\n\n[FUNDAMENTALS] Fetching comprehensive data for LLY...\n[FUNDAMENTALS] \u2713 Comprehensive data retrieved\n[FUNDAMENTALS] Calculating historical metrics for 2025-06-16...\n[FUNDAMENTALS] \u2713 Historical metrics calculated: 4\n[FUNDAMENTALS]   - Price: $804.63\n[FUNDAMENTALS]   - P/E: 88.48\n[FUNDAMENTALS]   - P/B: 45.68\n[FUNDAMENTALS]   - Current Ratio: 1.37\n[FUNDAMENTALS] Analyzing earnings history...\n[FUNDAMENTALS] Filtering earnings to before 2025-06-16\n[FUNDAMENTALS] \u2713 Earnings analysis complete (3/4 beats)\n[FUNDAMENTALS] Fetching SEC 10-K filing data...\n[FUNDAMENTALS] Generating analysis with gpt-4o-mini...\n[FUNDAMENTALS] \u2713 Analysis generated (3062 chars)\n\n[FUNDAMENTALS] \u2713 Analysis complete in 24.25s\n======================================================================\n\n## Fundamental Analysis Summary\n**Overall Assessment:** Eli Lilly and Company displays robust growth metrics and strong profitability, albeit at a high valuation relative to its earnings. The company's financial health shows some concerns due to its high debt levels, but the earnings quality remains strong with a solid beat rate.\n\n## Key Findings\n### Valuation\n- **Trailing P/E:** At 88.48, Eli Lilly's price-to-earnings ratio is significantly high, indicating the stock may be overvalued relative to its earnings.\n- **Price/Book Ratio:** At 45.68, this is much higher than typical sector averages, suggesting that investors are paying a premium for the company's book value.\n- **Price/Sales:** The ratio of 16.23 also indicates a high valuation compared to revenue, which could be a red flag for potential price corrections in the future.\n\n### Growth & Profitability  \n- **Revenue Growth:** An impressive 53.9% growth in revenue highlights strong demand and successful product offerings.\n- **Earnings Growth:** The earnings growth of 480.4% is exceptional, suggesting effective cost management or a significant increase in profitability from new products.\n- **Profit Margins:** With a profit margin of 31.0%, operating margin of 48.3%, and a gross margin of 83.0%, Eli Lilly demonstrates strong profitability, indicating efficient operations and strong pricing power.\n\n### Financial Health\n- **Current Ratio:** At 1.37, Eli Lilly's current ratio is below the ideal threshold of 1.5, suggesting potential liquidity concerns in meeting short-term obligations.\n- **Debt/Equity:** A high debt-to-equity ratio of 178.52 indicates that the company is heavily leveraged, which could pose risks, especially in a rising interest rate environment.\n- **Free Cash Flow:** Positive free cash flow of $1.40B indicates that the company is generating sufficient cash to invest in growth and service its debt.\n\n### Earnings Quality\n- **Earnings Beat Rate:** A beat rate of 75% indicates a strong performance relative to analysts' expectations, although the trend is declining.\n- **Trend in Earnings Surprises:** The trend shows a decrease in the size of earnings surprises, which could indicate that future performance may align more closely with analysts' expectations.\n\n## Investment Thesis\n**Bull Case:**\n1. Exceptional earnings growth of 480.4% suggests that the company is on a strong upward trajectory.\n2. High profit margins and return on equity (ROE) of 96.5% demonstrate strong operational efficiency and profitability.\n3. Positive free cash flow provides financial flexibility for future investments and debt management.\n\n**Bear Case:**\n1. High valuation metrics (P/E, P/B, P/S) raise concerns about overvaluation and potential price corrections.\n2. Elevated debt levels (Debt/Equity of 178.52) could pose financial risks, especially in adverse market conditions.\n3. The declining trend in earnings surprises may indicate potential challenges in maintaining growth momentum.\n\n## Final Recommendation\nRECOMMENDATION: HOLD - Confidence: Medium  \n**Risk Level:** Medium\n",
    "macro": "[MACRO] *** HISTORICAL MODE: Analyzing as of 2025-06-16 ***\n\n======================================================================\nMACRO ECONOMIC ANALYSIS\nPeriod: 7 days | Sector: All\n*** HISTORICAL MODE: As of 2025-06-16 ***\nTimestamp: 2025-12-01 08:35:29\n======================================================================\n\n[MACRO] Starting iterative analysis...\n[MACRO] Iteration 1/10\n[MACRO] \ud83d\udd27 Executing: get_market_indicators\n[MACRO] \ud83d\udd27 Tool: get_market_indicators (days=7)\n[MACRO] \u2713 Fetched 6/6 indicators\n[MACRO] \ud83d\udd27 Executing: get_sector_performance\n[MACRO] \ud83d\udd27 Tool: get_sector_performance (days=7)\n[MACRO] \u2713 Analyzed 9/9 sectors\n[MACRO] \ud83d\udd27 Executing: get_economic_indicators\n[MACRO] \ud83d\udd27 Tool: get_economic_indicators (days=7)\n[MACRO] \u2713 Economic indicators retrieved\n[MACRO] \ud83d\udd27 Executing: get_market_breadth\n[MACRO] \ud83d\udd27 Tool: get_market_breadth (days=7)\n[MACRO] \u2713 Breadth analysis complete\n[MACRO] Iteration 2/10\n[MACRO] \u274c Error in iterative analysis: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-KtddXWX7pT8yz52FN9uLjN7j on requests per day (RPD): Limit 10000, Used 10000, Requested 1. Please try again in 8.64s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'requests', 'param': None, 'code': 'rate_limit_exceeded'}}\n\n[MACRO] \u2713 Complete in 30.54s\n======================================================================\n\n# Macro Analysis (Partial)\n*Analysis Period: 7 days*\n**\u26a0\ufe0f HISTORICAL ANALYSIS AS OF 2025-06-16**\n*Successful Tools: 4, Failed: 0*\n\nRaw data gathered successfully:\n\nTools executed: get_market_indicators, get_sector_performance, get_economic_indicators, get_market_breadth\n\nRECOMMENDATION: NEUTRAL - Confidence: Low (Partial data)\n\n"
  },
  "bull_evidence": [
    {
      "source": "technical",
      "signal": "599 \u2192 Strong bullish momentum",
      "strength": 3,
      "keywords_matched": 3
    },
    {
      "source": "technical",
      "signal": "63, showing a recent positive momentum yet facing overbought conditions in several indicators",
      "strength": 2,
      "keywords_matched": 2
    },
    {
      "source": "technical",
      "signal": "- **Trend Strength:** Strong (as price is above most moving averages)",
      "strength": 2,
      "keywords_matched": 2
    },
    {
      "source": "technical",
      "signal": "[TECHNICAL] \u2713 Support: $706",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "As of June 16, 2025, LLY is experiencing a strong uptrend with the current price at $804",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "- **Moving Average Alignment:** Bullish (price > EMA_10 > SMA_20 > SMA_50)",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "## Momentum Indicators",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "- **Key Support:** $706",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "[NEWS] \u26a0\ufe0f Yahoo Finance has limited historical news support",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "', 'type': 'requests', 'param': None, 'code': 'rate_limit_exceeded'}}",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "**Lilly to buy gene-editing partner Verve for up to $1",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "3 billion deal to buy gene-editing biotech Verve Therapeutics, companies say**",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "**Eli Lilly Close To Buying Gene-Editing Biotech Verve Therapeutics - FT**",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "- June 16 - * ELI LILLY CLOSE TO BUYING GENE-EDITING BIOTECH VERVETHERAPEUTICS- FT * ELI LILLY IS IN ADVANCED TALKS TO BUY GENE EDITINGSTART-UPVERVE THE",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "**Sentiment:** BULLISH",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "- Bullish signals: 5",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "RECOMMENDATION: BUY - Confidence: Low",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "fundamental",
      "signal": "**Overall Assessment:** Eli Lilly and Company displays robust growth metrics and strong profitability, albeit at a high valuation relative to its earnings",
      "strength": 2,
      "keywords_matched": 2
    },
    {
      "source": "fundamental",
      "signal": "The company's financial health shows some concerns due to its high debt levels, but the earnings quality remains strong with a solid beat rate",
      "strength": 2,
      "keywords_matched": 2
    },
    {
      "source": "fundamental",
      "signal": "9% growth in revenue highlights strong demand and successful product offerings",
      "strength": 2,
      "keywords_matched": 2
    }
  ],
  "bear_evidence": [
    {
      "source": "technical",
      "signal": "- Given the overbought condition indicated by the RSI and Stochastic, along with a poor risk/reward ratio for a long setup, it would be advisable to consider exiting or shorting the position rather than entering long at this juncture",
      "strength": 2,
      "keywords_matched": 2
    },
    {
      "source": "technical",
      "signal": "41, Resistance: $821",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "The price is positioned within a high volatility environment, nearing a key resistance level",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "9 \u2192 **Overbought** (indicating potential for a pullback)",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "4 \u2192 Overbought territory (confirming potential overextension)",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "- **Key Resistance:** $821",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "- **Current Position:** Near resistance (+2",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "## Volatility & Risk",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "67:1 (Poor risk/reward ratio)",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "technical",
      "signal": "RECOMMENDATION: **SELL** - Confidence: Medium",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "news",
      "signal": "- Bearish signals: 0",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "fundamental",
      "signal": "48, Eli Lilly's price-to-earnings ratio is significantly high, indicating the stock may be overvalued relative to its earnings",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "fundamental",
      "signal": "5, suggesting potential liquidity concerns in meeting short-term obligations",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "fundamental",
      "signal": "52 indicates that the company is heavily leveraged, which could pose risks, especially in a rising interest rate environment",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "fundamental",
      "signal": "High valuation metrics (P/E, P/B, P/S) raise concerns about overvaluation and potential price corrections",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "fundamental",
      "signal": "52) could pose financial risks, especially in adverse market conditions",
      "strength": 1,
      "keywords_matched": 1
    },
    {
      "source": "fundamental",
      "signal": "**Risk Level:** Medium",
      "strength": 1,
      "keywords_matched": 1
    }
  ],
  "key_conflicts": [
    {
      "type": "recommendation_conflict",
      "severity": "CRITICAL",
      "analysts": [
        "news",
        "technical"
      ],
      "positions": {
        "news": "BUY",
        "technical": "SELL"
      },
      "description": "news says BUY while technical says SELL"
    },
    {
      "type": "recommendation_conflict",
      "severity": "MINOR",
      "analysts": [
        "fundamental",
        "technical"
      ],
      "positions": {
        "fundamental": "HOLD",
        "technical": "SELL"
      },
      "description": "fundamental says HOLD while technical says SELL"
    },
    {
      "type": "recommendation_conflict",
      "severity": "MINOR",
      "analysts": [
        "fundamental",
        "news"
      ],
      "positions": {
        "fundamental": "HOLD",
        "news": "BUY"
      },
      "description": "fundamental says HOLD while news says BUY"
    },
    {
      "type": "recommendation_conflict",
      "severity": "MINOR",
      "analysts": [
        "macro",
        "technical"
      ],
      "positions": {
        "macro": "HOLD",
        "technical": "SELL"
      },
      "description": "macro says HOLD while technical says SELL"
    },
    {
      "type": "recommendation_conflict",
      "severity": "MINOR",
      "analysts": [
        "macro",
        "news"
      ],
      "positions": {
        "macro": "HOLD",
        "news": "BUY"
      },
      "description": "macro says HOLD while news says BUY"
    }
  ],
  "consensus_points": [
    {
      "type": "partial_consensus",
      "recommendation": "HOLD",
      "count": 2,
      "analysts": [
        "fundamental",
        "macro"
      ],
      "description": "Partial consensus: fundamental and macro both say HOLD"
    }
  ],
  "research_priorities": [
    {
      "priority": "CRITICAL",
      "focus": "resolve_major_conflict",
      "description": "BUY vs SELL conflict - news says BUY while technical says SELL",
      "action": "Deep dive needed to determine which analyst is correct"
    },
    {
      "priority": "URGENT",
      "focus": "time_sensitive_event",
      "description": "Upcoming catalyst detected",
      "signal": "**Overall Assessment:** Eli Lilly and Company displays robust growth metrics and strong profitability, albeit at a high valuation relative to its earnings",
      "source": "fundamental",
      "action": "Research before event occurs"
    }
  ],
  "analyst_reports_summary": {
    "technical": {
      "recommendation": "SELL",
      "confidence": "Medium",
      "report_length": 2653,
      "has_data": true,
      "completed_successfully": true
    },
    "news": {
      "recommendation": "BUY",
      "confidence": "Low",
      "report_length": 4336,
      "has_data": true,
      "completed_successfully": true
    },
    "fundamental": {
      "recommendation": "HOLD",
      "confidence": "Medium",
      "report_length": 4146,
      "has_data": true,
      "completed_successfully": true
    },
    "macro": {
      "recommendation": "HOLD",
      "confidence": "Low",
      "report_length": 1737,
      "has_data": true,
      "completed_successfully": true
    }
  },
  "data_quality": {
    "status": "COMPLETE",
    "total_analysts": 4,
    "valid_analysts": 4,
    "failed_analysts": 0,
    "failed_list": [],
    "note": null
  },
  "llm_synthesis": "Synthesis error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o-mini in organization org-KtddXWX7pT8yz52FN9uLjN7j on requests per day (RPD): Limit 10000, Used 10000, Requested 1. Please try again in 8.64s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'requests', 'param': None, 'code': 'rate_limit_exceeded'}}",
  "synthesis_direction": "UNDETERMINED",
  "synthesis_confidence": "N/A"
}